Comparative Pharmacology
Head-to-head clinical analysis: DEFERASIROX versus JADENU SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERASIROX versus JADENU SPRINKLE.
DEFERASIROX vs JADENU SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron burden in transfusion-dependent patients.
Deferasirox is an oral iron chelator that selectively binds iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron overload by promoting iron excretion.
Initial: 20 mg/kg orally once daily. Maintenance: 20-40 mg/kg orally once daily (maximum 40 mg/kg/day).
Oral: Initial 20 mg/kg/day (max 30 mg/kg/day) administered once daily; titrate based on serum ferritin. For patients >14 years with serum ferritin >1000 mcg/L, use 20 mg/kg/day. Sprinkle capsules can be opened and contents sprinkled on soft food.
None Documented
None Documented
Clinical Note
moderateDeferasirox + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateDeferasirox + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox."
Clinical Note
moderateCarprofen + Deferasirox
Terminal elimination half-life is 8–16 hours in patients with transfusional iron overload; higher iron burden prolongs half-life due to enterohepatic recirculation.
8–28 hours (mean 11–19 hours); prolonged half-life correlates with iron overload and may require dose adjustments.
Primarily fecal (84%) as unchanged drug via biliary excretion; renal excretion accounts for approximately 8% as unchanged drug and metabolites.
Primarily fecal (84% of absorbed dose); renal excretion accounts for approximately 8% of total clearance.
Category C
Category C
Iron Chelator
Iron Chelator
"The risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox."